Novo Nordisk, armed with Wegovy green light, preps aggressive push to build obesity market

After Novo Nordisk last week snagged its hotly anticipated obesity green light for semaglutide, the drugmaker is wasting no time kicking the launch into gear.

With its Wegovy approval in hand, the company is prepping for “one of the fastest Novo Nordisk launches after approval ever,” Camilla Sylvest, Novo’s head of commercial strategy and corporate affairs, said on a call with investors Monday. Wegovy will debut Thursday, June 10, less than a week after receiving the FDA’s blessing, and will hit pharmacy shelves June 18.